ClinicalTrials.gg
CompletedNCT03472365Updated Jan 11, 2024Results posted

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

A Phase 2 interventional study of SHR-1210 and Capecitabine in Gastric Cancer and GastroEsophageal Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing camrelizumab in Stomach Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. camrelizumab · Stomach Neoplasms.

Enrollment
10th of 33
67 · median 46
Started
2018
with 3 others
Phase 2
24 of 33
4 open now
Registered
3rd of 33
by date
Lead sponsor
3 of 33
Jiangsu HengRui Medicine Co., Ltd.

Among the 33 studies testing camrelizumab in Stomach Neoplasms, this one is the 10th largest by enrollment, is one of 4 that started in 2018, is one of 24 in phase 2, and was the 3rd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 33 studies testing camrelizumab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing camrelizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Read the detailed description

Approximately 110 participants will be assigned to SHR-1210 + capecitabine + oxaliplatin combination therapy (Cohort 1), or SHR-1210 + apatinib combination therapy (Cohort 2).

03

Conditions studied

  • Gastric Cancer
  • GastroEsophageal Cancer

Browse trials for

Keywords

  • PD-1
  • SHR-1210
  • Capecitabine
  • Oxaliplatin
  • Apatinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has - or cytologically-confirmed diagnosis of locally advanced unresectable or adenocarcinoma of stomach or the esophagogastric junction (GEJ).
  • Age ≥ 18 years old, male or female.
  • NO previous therapy for advanced/metastatic disease of GC/GEJ (including inhibitor). Subjects with previous /neo-adjuvant therapy completed more than 6 months can be enrolled.
  • Has per 1.1.
  • ≥ 12 weeks.
  • Eastern Cooperative Group () performance status of 0 to 1.
  • Has adequate organ function.
  • Females of (FOCBP), who are not surgically sterile or , must conduct pregnancy test (serum or urine) within 7 days before enrollment, and must not be pregnant or breast-feeding women. If the result is negative, she must agree to use adequate during the experiment and 3 months after the last administration of the test drugs. And non-sterilized males who are sexually active must agree to use adequate contraception during the experiment and 3 months after the last administration of the test drugs.

Exclusion criteria

Exclusion Criteria:

  • Has known -positive status.
  • Has received prior therapy with an , anti-PD-L1, or anti-CTLA-4 antibody, or a VEGFR inhibitor.
  • Has known active central nervous system .
  • Has received a within 4 weeks prior to the first dose of study treatment.
  • With any active disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded.
  • cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure ( (NYHA) class > 2), or ventricular arrhythmia which need medical intervention.
  • Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg.
  • Coagulation abnormalities ( > 1.5 or APTT > 1.5×), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m\^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd if there is no PD.

    Biological: SHR-1210 · Drug: Capecitabine · Drug: Oxaliplatin · Drug: Apatinib

  • Experimental
    Cohort 2

    Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continuous oral administration of each 3-week cycle.

    Biological: SHR-1210 · Drug: Apatinib

Interventions

  • BiologicalSHR-1210

    SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

    Also known as: Camrelizumab

  • 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.

  • 130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.

  • 375 mg administered as continuous oral once daily (QD) of each 3-week cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1.

    Time frame: Up to approximately 6 months.

Secondary outcomes

  1. Progression-free Survival (PFS) Per RECIST 1.1

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months.

  2. Duration of Response (DOR) Per RECIST 1.1

    For participants who demonstrate CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), DOR is defined as the time from first documented evidence of CR or PR until disease progression per RECIST 1.1 based on assessments by blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months.

  3. Disease Control Rate (DCR) Per RECIST 1.1

    DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.

    Time frame: Up to 24 months.

  4. Number of Subjects With Treatment-related Adverse Events (AEs)

    Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.

    Time frame: Up to 24 months.

07

Results

Posted Jan 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started4819
Completed4819
Not completed00

Outcome measures

PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1.

Time frame:
Up to approximately 6 months.
Reported as:
Number · percentage
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentageCohort 1Cohort 2
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.158.3 (43.2 to 72.4)10.5 (1.3 to 33.1)
SecondaryProgression-free Survival (PFS) Per RECIST 1.1

PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.

Time frame:
Up to 24 months.
Reported as:
Median · months
Progression-free Survival (PFS) Per RECIST 1.1
monthsCohort 1Cohort 2
Progression-free Survival (PFS) Per RECIST 1.16.768 (5.552 to 9.495)2.793 (1.380 to 4.764)
SecondaryDuration of Response (DOR) Per RECIST 1.1

For participants who demonstrate CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), DOR is defined as the time from first documented evidence of CR or PR until disease progression per RECIST 1.1 based on assessments by blinded independent central review or death due to any cause, whichever occurs first.

Time frame:
Up to 24 months.
Reported as:
Median · months
Duration of Response (DOR) Per RECIST 1.1
monthsCohort 1Cohort 2
Duration of Response (DOR) Per RECIST 1.15.749 (4.370 to 8.345)NA (2.694 to NA)
SecondaryDisease Control Rate (DCR) Per RECIST 1.1

DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.

Time frame:
Up to 24 months.
Reported as:
Number · percentage
Disease Control Rate (DCR) Per RECIST 1.1
percentageCohort 1Cohort 2
Disease Control Rate (DCR) Per RECIST 1.193.8 (82.8 to 98.7)57.9 (33.5 to 79.7)
SecondaryNumber of Subjects With Treatment-related Adverse Events (AEs)

Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.

Time frame:
Up to 24 months.
Reported as:
Number · participants
Number of Subjects With Treatment-related Adverse Events (AEs)
participantsCohort 1Cohort 2
Number of Subjects With Treatment-related Adverse Events (AEs)4818

Adverse events

Collected over 32 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 114/48 (29.2%)22/48 (45.8%)48/48 (100%)
Cohort 29/19 (47.4%)12/19 (63.2%)19/19 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCohort 1Cohort 2
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/483/19
Liver injuryHepatobiliary disorders0/482/19
Platelet count decreasedInvestigations5/480/19
Gastrointestinal haemorrhageGastrointestinal disorders3/481/19
DiarrhoeaGastrointestinal disorders2/481/19
IleusGastrointestinal disorders1/481/19
Upper gastrointestinal haemorrhageGastrointestinal disorders0/481/19
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/481/19
Alanine aminotransferase increasedInvestigations0/481/19
Aspartate aminotransferase increasedInvestigations0/481/19
Most frequent other events
Showing 10 of 112
Most frequent other events
EventCohort 1Cohort 2
Reactive capillary endothelial proliferationImmune system disorders38/480/19
Platelet count decreasedInvestigations32/484/19
Neutrophil count decreasedInvestigations30/487/19
White blood cell count decreasedInvestigations26/487/19
AnaemiaBlood and lymphatic system disorders24/489/19
NauseaGastrointestinal disorders24/485/19
Alanine aminotransferase increasedInvestigations16/489/19
Aspartate aminotransferase increasedInvestigations21/486/19
PyrexiaGeneral disorders15/488/19
Gamma-glutamyltransferase increasedInvestigations15/488/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years old)Cohort 1Cohort 2Total
Median56.0 (23 to 73)62.0 (27 to 72)59.0 (23 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female371653
Male11314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian481967
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Total
China481967
08

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, Beijing, China
09

References and documents

Publications

  • Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y, Shen L. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2021 Jun 1;27(11):3069-3078. doi: 10.1158/1078-0432.CCR-20-4691. Epub 2021 Mar 25. PubMed 33766817 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Nov 2020, 31 months.

Results were first posted in Jan 2024, 3 years 1 month after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 31 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2018
First posted
Mar 21, 2018
StartActual
Apr 2, 2018
Primary completionActual
Nov 25, 2020
CompletionActual
Nov 25, 2020
Results first posted
Jan 11, 2024
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03472365
Responsible party
Sponsor
First posted
Mar 21, 2018
Start date
Apr 2, 2018
Primary completion
Nov 25, 2020
Completion
Nov 25, 2020
Results posted
Jan 11, 2024
Last update
Jan 11, 2024

Study contacts

Lin Shen, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib

Start the discussion